Pfizer Inc. (NYSE:PFE) Shares Sold by Bank OZK

Bank OZK lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 24,424 shares of the biopharmaceutical company’s stock after selling 607 shares during the period. Bank OZK’s holdings in Pfizer were worth $648,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Sage Investment Counsel LLC bought a new position in shares of Pfizer during the fourth quarter worth about $213,000. SVB Wealth LLC bought a new position in shares of Pfizer during the fourth quarter worth about $13,873,000. Tower Bridge Advisors grew its position in shares of Pfizer by 2.0% during the fourth quarter. Tower Bridge Advisors now owns 64,997 shares of the biopharmaceutical company’s stock worth $1,724,000 after acquiring an additional 1,296 shares during the last quarter. Motco grew its position in shares of Pfizer by 0.6% during the fourth quarter. Motco now owns 140,570 shares of the biopharmaceutical company’s stock worth $3,729,000 after acquiring an additional 868 shares during the last quarter. Finally, Altrius Capital Management Inc grew its position in shares of Pfizer by 11.2% during the fourth quarter. Altrius Capital Management Inc now owns 169,634 shares of the biopharmaceutical company’s stock worth $4,500,000 after acquiring an additional 17,050 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.43 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $149.78 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a 50-day moving average of $26.35 and a 200-day moving average of $27.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.51%. Pfizer’s dividend payout ratio is currently 121.99%.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.